Breast Cancer
Conditions
Interventions
This is a two-arm, single-blind, randomized controlled clinical study. The Intervention Group will be composed of 30 women with breast cancer undergoing antineoplastic treatment who will receive appli
E02.594.540
Sponsors
Universidade Federal do Paraná
Liga Paranaense de Combate ao Câncer
Eligibility
Sex/Gender
Female
Age
21 Years to No maximum
Inclusion criteria
Inclusion criteria: Women over the age of 21; with a clinical diagnosis of unilateral or bilateral primary breast cancer; undergoing conventional adjuvant antineoplastic treatment (chemotherapy, radiotherapy or hormonal therapy); whether or not undergoing surgical treatment to remove the solid tumor; with a score between 0 to 2 on ECGO-OS (Eastern Cooperative Oncology Group Performance Status); with the ability to communicate in Portuguese; residing in Curitiba or the Metropolitan Region; available to participate in research interventions in a 10-week follow-up schedule
Exclusion criteria
Exclusion criteria: Women under 21; who do not agree to participate in this study; illiterate or who present cognitive deficit determined by the MMSE questionnaire - Mini Mental State Examination; hearing deficit that prevents understanding verbal instructions; with the presence or suspicion of metastatic areas, presence of allergies or skin diseases (atopic dermatitis, contact dermatitis, psoriasis or rosacea); pregnant or lactating women; women with a body mass index (BMI) above 40 (due to the presence of comorbidities related to obesity that may interfere with the results); contraindications for the application of mILIB will (cardiogenic shock, arterial hypotension, heart disease, circulatory failure in stages II and III, anemia, sick sinus syndrome, existence of blood coagulopathies, personal history of cancer at the application site); hemorrhagic, infected or photosensitive area; women with phototype VI on the Fitzpatrick scale confirmed by the analyzer as phototype V; blood tumors; pacemaker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| It is expected to find a one-point reduction in the severity of adverse events related to adjuvant antineoplastic treatment, with a one-point reduction in severity on the scale of the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events | — |
Secondary
| Measure | Time frame |
|---|---|
| It is expected to find a 20% reduction in pain, sensation of heaviness and perception of limb edema verified by the 11-point Numerical Scale | — |
Countries
Brazil
Contacts
Public ContactRaciele Guarda Korelo
Universidade Federal do Paraná
Outcome results
None listed